Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    INT230-6
Previous Study | Return to List | Next Study

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03058289
Recruitment Status : Recruiting
First Posted : February 20, 2017
Last Update Posted : July 9, 2020
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb
Information provided by (Responsible Party):
Intensity Therapeutics, Inc.

Brief Summary:
This study evaluates the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study is being conducted in patients with several types of refractory cancers including those at the surface of the skin (breast, squamous cell, head and neck) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also plans to test INT230-6 in combination with anti-PD-1 and anti-CTLA-4 antibodies.

Condition or disease Intervention/treatment Phase
Breast Cancer Head and Neck Cancer Squamous Cell Carcinoma Lymphoma Pancreatic Cancer Liver Cancer Colon Cancer Lung Cancer Bile Duct Cancer Chordoma of Sacrum Sarcoma Drug: INT230-6 Biological: anti-PD-1 antibody Biological: anti-CTLA-4 antibody Phase 1 Phase 2

Detailed Description:

INT230-6 is comprised of a 3 agents in a fixed ratio - a cell permeation enhancer and two, potent anti-cancer payloads (cisplatin and vinblastine sulfate). The penetration enhancer facilitates dispersion of the two drugs throughout injected tumors and enables increased diffusion into cancer cells. (Nonclinical safety studies showed no findings following drug injection into healthy tissues.)

Historically physicians administer the two active drugs comprising INT230-6 by intravenous (IV) infusion to achieve a systemic blood level at the limit of tolerability. The objective is destroy both visible tumors and unseen circulating cancer cells (micro-metastases). Unfortunately, dosing drugs IV delivers only a small amount with a low concentration at the tumor site. This approach especially for late stage cancers is not highly effective and often quite toxic to the patient.

Attempts at direct intratumoral injection with chemotherapeutic agents have not shown the ability to treat the injected tumor, non-injected tumors or micro-metastases. This lack of efficacy for local administration is due possibly to poor dispersion and a lack of cell uptake of the agents.

Due to the use of the novel cell penetration enhancing agent INT230-6 treatment demonstrates strong efficacy in animals having large tumors. The Sponsor's in vivo, non-clinical data shows that INT230-6 thoroughly saturates and kills injected tumors. In addition, the drug induces an adaptive (T-cell mediated) immune response that attacks not only the injected tumor, but non-injected tumors and unseen micro-metastases. Cured animals become permanently immunized against the type of cancer that INT230-6 eliminates.

Clinical trial IT-01 seeks to determine the safety and potential efficacy of dosing INT230-6 directly into several different types of cancers. In addition animal studies showed a strong synergy of INT230-6 with immune modulation agents. Thus as part of study IT-01 the Sponsor seeks to understand the safety and efficacy of INT230-6 when administered in combination with immuno-therapeutic agents such as antibodies that target Programmed Cell Death (PD-1 or anti-PD-1) and Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4 or anti-CTLA-4) receptors.

This study seeks to understand whether tumor regression can be achieved and patient outcomes improved.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

There were 6 cohorts in the escalation portion of the protocol. Five dosed INT230-6 alone and one was combined with pembrolizumab. Cohorts A and B1 treated superficial tumors at a 1:4 ratio of drug to tumor with a low tumor load once per month. Cohort EA was similar to cohort A with INT230-6 every 2 weeks. Cohort EC escalated the total and maximal dose per any one tumor to a ratio of 1:2 & dosed every two weeks. Cohort EC2 explored a drug load ratio of 1:3 and escalated the dose per tumor further. Cohort DEC combined INT230-6 with a fixed amount of pembrolizumab.

On-going, non-escalation cohorts include 1) monotherapy INT230-6 cohort (EC3) dosed every two weeks 2) INT230-6 in a combination with pembrolizumab (DEC2) and 3) INT230-6 in combination with ipilimumab (FEC). Other specific regimens or combinations of INT230-6 may be designated by the Study Steering Committee.

Masking: None (Open Label)
Masking Description: There is no masking and all patients will receive INT230-6 treatments.
Primary Purpose: Treatment
Official Title: A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
Actual Study Start Date : February 9, 2017
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : October 2023


Arm Intervention/treatment
Experimental: Cohort A

INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.

Closed to enrollment

Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Experimental: Cohort B1

INT230-6 injections every 28 days for 5 sessions into deep tumors, low starting dose, low drug concentration per tumor

Closed to enrollment

Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Experimental: Cohort EA

INT230-6 injections every 2 weeks for 5 sessions into superficial tumors, medium starting dose, low drug concentration per tumor

Closed to enrollment

Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Experimental: Cohort EC

INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor

Closed to enrollment

Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Experimental: Cohort EC2
INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC
Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Experimental: Cohort DEC: Safety with INT230-6

INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody Keytruda (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.

Closed to enrollment

Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Biological: anti-PD-1 antibody
The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
Other Names:
  • pembrolizumab
  • Keytruda
  • MK-3475

Experimental: EC3: INT230-6 monotherapy fixed maximal dose
INT230-6 injections every 2 weeks for 5 sessions at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.
Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Experimental: DEC2: INT230-6 combined with pembrolizumab
INT230-6 per the dosing of cohort EC3 combined with Keytruda (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.
Drug: INT230-6

INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.

The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.

The drug is stored frozen and must be dosed at room temperature.

The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area


Biological: anti-PD-1 antibody
The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
Other Names:
  • pembrolizumab
  • Keytruda
  • MK-3475

Experimental: FEC: INT230-6 combined with ipilimumab
INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.
Biological: anti-CTLA-4 antibody
The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
Other Names:
  • ipilimumab
  • Yervoy
  • BMS-734016




Primary Outcome Measures :
  1. Rate and severity of treatment-emergent adverse events ≥ grade 3 attributed to study drug using the NCI Common Terminology Criteria for Adverse Events (CTCAE v.4.03) (Scale 1 to 5) [ Time Frame: Up to 5 years ]

    The primary objective is to assess the safety and tolerability of single and multiple intratumoral doses of INT230-6 in subjects with advanced or recurrent malignancies. This will be assessed by the rate of ≥ grade 3 AE's attributed to INT230-6 and not the underlying disease.

    All recorded adverse events will be listed and tabulated by system organ class, preferred term, and dose and coded according to the most current version of MedDRA. The incidence of adverse events will be tabulated and reviewed for potential significance and clinical importance.

    Adverse Events will be summarized for all reported data and by study period: a) up to and including 28 days post last dose of initial treatment, and b) from first dose of re-initiation of treatment, for subjects who re-initiate study therapy while in follow-up, up to 28 days post-dose of the last re-treatment dose.



Secondary Outcome Measures :
  1. Preliminary Efficacy: Control or Regression of Injected Tumors by Measurement of Length, Width and Height (in centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging to Calculate Tumor Volumes (cubic centimeters) Over Time. [ Time Frame: Up to 5 years ]

    Assess the preliminary efficacy of INT230-6 by measuring the disease control rate (CR+PR+SD) as assessed by iRECIST.

    Assess INT230-6's effect on tumors by measuring the length, width and height (centimeters) of injected tumors during the dosing and afterward.


  2. Determine pharmacokinetic parameter Peak Plasma (Cmax in ng/mL) of each of the 3 main components of INT230-6. [ Time Frame: Up to 4 years ]
    Characterize the peak plasma profile for the three INT230-6 components after single and then multiple IT tumor site injections for safety purposes.

  3. Determine key pharmacokinetic parameter, Area Under the Curve (AUC) (ng*hr/mL) of each of the 3 main components of INT230-6. [ Time Frame: Up to 4 years ]
    Characterize the pharmacokinetic AUC profile of each of the three INT230-6 components for AUC after single IT tumor site injection for safety purposes.

  4. Key pharmacokinetic parameters, half live (hours) of each of the 3 main components of INT230-6. [ Time Frame: Up to 4 years ]
    Characterize the half life of each of the three INT230-6 components after single and multiple IT tumor site injections for safety purposes.


Other Outcome Measures:
  1. Exploratory: Control or Regression of Non Injected Tumors by Measurement of Length (in centimeters) Radio-graphically Using Computer Tomography or Magnetic Resonance Imaging. [ Time Frame: Up to 18 months ]
    Characterize response in non-injected lesions (up to 5) using length (cm) as the key parameter for measurement.

  2. Exploratory: Blood, Genetic and Tissue Biomarker Identification from cell flow phenotyping, tissue analysis, genetic SNP analysis. [ Time Frame: Up to 2 months ]
    Evaluate various tumor and anti-tumor immune response biomarkers from blood, tumor tissue that may correlate with tumor response. Flow and tissue panels may include Live-Dead, CD3, CD4, CD8, FoxP3, Ki-67, ICOS, DAPI, PD-1, LAG-3, TIM-3, CTLA-4 and analysis of blood serum cytokine such as Th1/Th2, IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12 p70, IL-13, and TNF-α.

  3. Exploratory: Overall Subject Outcome [ Time Frame: Up to 3 years ]
    Evaluate overall response by iRECIST including survival



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

INT230-6 monotherapy Cohorts EC2 and EC3, combination with Keytruda cohort DEC2 and combination with Yervoy cohort FEC. Where criteria diverge the DEC2 and FEC specific criteria will be noted.

  1. The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  2. Men and Women > 18 years of age on the day of signing consent.
  3. For cohort EC2: Have an Eastern Cooperative Oncology Group (ECOG) performance status < or = 2; for cohort DEC and FEC < or equal to 1.
  4. Includes subjects with loco-regional disease that have relapsed/recurred within 6 months of chemo-radiation and who have no standard of care.
  5. Includes subjects with metastatic disease who must have failed approved standard therapies that have a clinically significant survival benefit. Failure of all approved therapies that have a modest or marginal impact on survival is not required as long as the treating physician believes that treatment on study is appropriate for the subject and documents that the subject elects to defer the approved therapies.

    Note: There is no limit on the number of prior therapies that a patient (subject) may have received prior to enrollment in any cohort.

  6. Subjects must have measurable disease by RECIST 1.1 criteria including one target tumor for injection. Superficial tumors must have one tumor greater than or equal to 1.0 cm, deep tumors greater than or equal to 1.0 cm (as measured by caliper (for non-injected tumors only) or image guidance).
  7. Subjects must have a minimum of one injectable lesion as determined by the investigator (for superficial tumors) or radiologist (deep tumors); Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  8. Prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer: systemic or IT) must have been completed at least 4 weeks prior to dosing (with the exception of kinase inhibitors or other short half-life drugs, a 2 weeks washout is acceptable prior to treatment).and all adverse events have either returned to baseline or stabilized; note: subjects who have received prior platinum therapy are eligible irrespective of their response.
  9. Prior systemic radiation therapy (either IV, intrahepatic or oral) completed at least 4 weeks prior to study drug administration.
  10. Prior focal radiotherapy completed at least 2 weeks prior to study drug administration.
  11. Prior major treatment-related surgery completed at least 4 weeks prior to study drug administration.
  12. No prior primary or metastatic brain or meningeal tumors unless clinically and radiographically stable as well as off steroid therapy for at least 2 months.
  13. Life expectancy ≥8 weeks.
  14. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP)
    2. A WOCBP Subjects who may become pregnant or who are sexually active with a partner who could become pregnant agree to use an effective form of barrier contraception during the study and for at least 60 days in monotherapy (for the pembrolizumab combination please see cohort DEC and for the ipilimumab combination see cohort FEC for the pregnancy criteria) for female subjects.

    (Male subjects must agree to use contraception during the study for 180 days after administration of study drug).

  15. Have adequate organ function as defined by the below screening laboratory values that must meet the following criteria:

    1. WBC ≥2000/μL (≥2 x 10^9/L)
    2. Neutrophils ≥1000/μL (≥1 x 10^9/L); For DEC combination ≥2000/μL (≥2 x 10^9/L); for FEC combination (≥1500/μL (≥1 x 10^9/L)
    3. For subjects with planned superficial only injections PT, aPTT, and INR ≤1.5 × ULN Platelets ≥70x103/μL (≥ 70 x 109/L); Hemoglobin ≥8 g/dL (≥80 g/L) (superficial tumor dosing only).
    4. Creatinine within the institution's laboratory upper limit of normal or calculated creatinine clearance >50 ml/min
    5. ALT (SGOT)/AST (SGPT) ≤2.5 x ULN without, and ≤ 5 x ULN with hepatic metastases
    6. Bilirubin ≤2 x ULN (except subjects with Gilbert's syndrome, who must have total bilirubin <3.0 mg/dL (<52 µmol/L); For DEC and FEC cohort combinations ≤1.5 x ULN.
    7. For subjects with planned deep tumor injections: PT, aPPT, and INR within normal limits; Platelet count ≥100,000/μL; hemoglobin ≥ 9 gm/dL.

Note: ALT (SGPT) =alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT) =aspartate aminotransferase (serum glutamic oxaloacetic transaminase); ULN=upper limit of normal.

1 Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks.

Additional Inclusion Criteria for DEC2 cohort (anti-PD1 combination, Keytruda (pembrolizumab)) Population: Subjects with histologically or cytologically confirmed advanced or metastatic Pancreatic, Cholangiocarcinoma, non-MSI-H and/or MMR proficient colorectal cancer, and Squamous Cell Carcinoma tumors.

Additional Inclusion Criteria for FEC cohort (anti-CTLA-4 combination, Yervoy (ipilimumab)) Population: Subjects with histologically or cytologically confirmed advanced or metastatic Hepatocellular carcinoma (HCC), breast cancer regardless of histology (BC) or soft tissue sarcoma

NOTE: There are Additional Inclusion Criteria for the combination arms - refer to Investigative site for details.

Exclusion Criteria:

For INT230-6 Monotherapy cohort EC2, EC3, cohort DEC2-Keytruda combination and cohort FEC-Yervoy combination

Subjects who exhibit any of the following conditions at screening will not be eligible for admission into the study: DEC or FEC cohorts have additional criteria.

  1. History of severe hypersensitivity reactions to cisplatin or vinblastine or other products of the same class.
  2. Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the subject has been disease-free for at least 5 years.
  3. Underlying medical condition that, in the Principal Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity determination or adverse events.
  4. Concurrent medical condition requiring the use of immunosuppressive medications, or systemic corticosteroids; systemic corticosteroids must be discontinued at least 4 weeks prior to dosing. Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if the subject is on a stable dose. Non-absorbed intra-articular steroid injections will be permitted; or use of other investigational drugs (drugs not marketed for any indication) within 30 days prior to study drug administration. Use of steroids as prophylactic treatment for subjects with contrast allergies to diagnostic imaging contrast dyes will be permitted.
  5. For deep tumor cohorts, subjects who require uninterrupted anticoagulants of any type, on daily aspirin therapy or NSAIAs.

NOTE: There are Additional Exclusion Criteria for combination arms - please refer to Investigative site for details.

Pregnancy Exclusion:

A WOCBP who has a positive urine pregnancy test (e.g. within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03058289


Contacts
Layout table for location contacts
Contact: Samira Irby 678-231-1604 sirby@ce3inc.com
Contact: Karen Du 203-221-1290 KDu@intensitytherapeutics.com

Locations
Layout table for location information
United States, California
USC Norris Recruiting
Los Angeles, California, United States, 90033
Contact: Xiomara Menendez    323-409-4368    xiomara.menendez@med.usc.edu   
Contact: Lorraine Martinez    323-865-0967    Lorraine.Martinez@med.usc.edu   
USC HOAG Recruiting
Newport Beach, California, United States, 92663
Contact: Cristina de Leon    949-764-5543    cristina.deleon@hoag.org   
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21205
Contact: Jennifer Hale, RN    410-502-5140    phase1trials@exchange.johnshopkins.edu   
Principal Investigator: Nilofer Azad, MD         
United States, Massachusetts
UMASS Memorial Medical Center Recruiting
Worcester, Massachusetts, United States, 01655
Contact: Cancer Research Office    508-856-3216    cancer.research@umassmed.edu   
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Lisa Olmos, RN    212-342-5162    cancerclinicaltrials@cumc.columbia.edu   
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111-2497
Contact: Ikenna Opurum    215-728-5518    Ikenna.Opurum@fccc.edu   
Principal Investigator: Anthony J. Olszanski, MD, RPh         
Canada, Ontario
Princess Margaret Cancer Center - University Health Network Recruiting
Toronto, Ontario, Canada, M5G 1Z5
Contact: Oncology Referral    416-946-4575      
Sponsors and Collaborators
Intensity Therapeutics, Inc.
Merck Sharp & Dohme Corp.
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Ian B. Walters, M.D. Intensity Therapeutics
Study Chair: Lillian Siu, M.D., FRCP Princess Margaret Hospital, Canada
Principal Investigator: Anthony El-Khoueiry, M.D. USC Norris and HOAG sites
Principal Investigator: Anthony J. Olszanski, M.D., RPh Fox Chase Cancer Center
Principal Investigator: Nilofer Azad, M.D. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Principal Investigator: Giles F Whalen, M.D. UMASS Memorial Medical Group
Principal Investigator: Matthew Ingham, M.D. Columbia University
Layout table for additonal information
Responsible Party: Intensity Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03058289    
Other Study ID Numbers: IT-01
KEYNOTE KN-A10 ( Other Identifier: Merck Sharp & Dohme Corp )
CA184-592 ( Other Identifier: Bristol Myers Squibb Company )
First Posted: February 20, 2017    Key Record Dates
Last Update Posted: July 9, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Intensity Therapeutics, Inc.:
INT230-6
Neoplasm
Malignancy
Intratumoral
Intralesional
anti-PD-1 antibodies
Immuno therapy
Dose escalation
Platinum
Intensity Therapeutics
Cisplatin
Vinblastine
PD-1
Vinca
Keytruda
Pembrolizumab
CTLA-4
Carcinoma
Yervoy
Ipilimumab
Keynote A10
CA184-592
Additional relevant MeSH terms:
Layout table for MeSH terms
Bile Duct Neoplasms
Cholangiocarcinoma
Chordoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Biliary Tract Neoplasms
Bile Duct Diseases
Biliary Tract Diseases
Adenocarcinoma
Neoplasms, Germ Cell and Embryonal
Pembrolizumab
Ipilimumab
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents